Zions Bancorporation N.A. Purchases 89,992 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Zions Bancorporation N.A. lifted its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 108.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 173,180 shares of the medical technology company’s stock after purchasing an additional 89,992 shares during the quarter. Zions Bancorporation N.A. owned 0.12% of Alphatec worth $963,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Comerica Bank boosted its position in shares of Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Alphatec in the 1st quarter valued at $141,000. Van ECK Associates Corp lifted its position in Alphatec by 11.8% in the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after acquiring an additional 1,300 shares in the last quarter. Cetera Advisors LLC lifted its position in Alphatec by 15.6% in the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 1,720 shares in the last quarter. Finally, Net Worth Advisory Group bought a new stake in Alphatec in the 3rd quarter valued at $76,000. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Down 4.4 %

Shares of ATEC opened at $8.73 on Friday. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34. The firm has a market cap of $1.24 billion, a P/E ratio of -6.82 and a beta of 1.31. The firm’s 50-day simple moving average is $6.26 and its 200 day simple moving average is $8.42. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Insider Activity at Alphatec

In other Alphatec news, Director David M. Demski purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was purchased at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the transaction, the director now owns 288,441 shares in the company, valued at $1,635,460.47. The trade was a 20.97 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a research report on Thursday, October 31st. Morgan Stanley cut shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Friday, August 30th. Finally, Wells Fargo & Company lowered their price target on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.